Calla Lily Clinical Care is a UK-based medtech developing the Callavid, a tampon-shaped device designed to deliver progesterone more effectively and hygienically than vaginal pessaries. The Callavid is intended to reduce leakage, discomfort and anxiety associated with current progesterone administration. It targets women experiencing threatened miscarriage and early pregnancy complications; the article notes about 150,000 women in the UK are affected annually. The device is currently undergoing clinical trials. Trials will be led by Professor Siobhan Quenby MBE at University Hospitals Coventry and Warwickshire. The company has secured £1M in funding from the National Institute for Health and Care Research (NIHR).

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2025